NCT07521293

Brief Summary

This study was designed to investigate predictors of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), with a particular focus on the potential relationship between venous congestion and intracranial pressure dynamics. Among HFpEF patients, those with AF exhibited significantly higher right atrial pressure (RAP), larger right atrial area, higher CHA₂DS₂-VA scores, and increased optic nerve sheath diameter (ONSD), a noninvasive surrogate marker of intracranial pressure. In multivariable logistic regression analysis, increased ONSD, elevated RAP, larger right atrial area, and higher CHA₂DS₂-VA score remained independently associated with AF, suggesting that both systemic venous congestion and intracranial pressure-related mechanisms may contribute to AF susceptibility in this population. These findings support the hypothesis of a cardio-cerebral interaction in HFpEF, in which elevated right-sided filling pressures may impair cerebrospinal fluid drainage, increase intracranial pressure, and potentially promote AF through autonomic and hemodynamic pathways.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
309

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 14, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 20, 2026

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

April 3, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 9, 2026

Completed
Last Updated

April 9, 2026

Status Verified

March 1, 2026

Enrollment Period

5 months

First QC Date

April 3, 2026

Last Update Submit

April 3, 2026

Conditions

Keywords

HFpEF;Atrial fibrillationVenous congestionOptic nerve sheath diameterCranial MRIEchocardiographyIntracranial pressure

Outcome Measures

Primary Outcomes (2)

  • Atrial fibrillation status (AF vs sinus rhythm) in HFpEF patients

    The primary analysis evaluates the association of ONSD, RAP, and the right atrial area with AF status.

    Baseline

  • Presence of atrial fibrillation in patients with HFpEF

    The rhythm status was measured by electrocardiography and documented. The primary analysis evaluates the association of ONSD, RAP, and right atrial area with AF status.

    At baseline (cross-sectional assessment)

Study Arms (3)

Group 1

Individuals without HFpEF or atrial fibrillation were used as the reference group.

Diagnostic Test: Echocardiography

group2

HFpEF With Sinus Rhythm

Diagnostic Test: Echocardiography

group 3

HFpEF With Atrial Fibrillation

Diagnostic Test: Echocardiography

Interventions

EchocardiographyDIAGNOSTIC_TEST

Standard transthoracic echocardiography, including EF, E/e', TRV, atrial areas, SPAP, and estimated right atrial pressure.

Group 1group 3group2

Eligibility Criteria

Age60 Years - 78 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total of 309 subjects aged approximately 60-78 years with available cranial MRI data were enrolled, including a control group (n = 106), HFpEF patients in sinus rhythm (n = 111), and HFpEF patients with atrial fibrillation (n = 92).

You may qualify if:

  • Adults aged approximately 60-78 years with available cranial MRI , HFpEF patients in sinus rhythm, HFpEF patients with atrial fibrillation No HFpEF patients(control) -

You may not qualify if:

  • Patients with heart failure and reduced ejection fraction (EF \<50%), known intracranial hypertension, optic nerve or other neurological disorders, chronic obstructive pulmonary disease, clinically significant goiter, liver cirrhosis, renal failure, severe valvular heart disease, congenital heart disease, and advanced diabetes mellitus requiring insulin therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Ataturk Strh

Ankara, Ankara, 06310, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Atrial FibrillationHyperemia

Interventions

Echocardiography

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsVascular Diseases

Intervention Hierarchy (Ancestors)

Cardiac Imaging TechniquesDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisUltrasonographyHeart Function TestsDiagnostic Techniques, Cardiovascular

Study Officials

  • şahbender koç, MD

    AnkaraAtatürk STRH

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
cardıologıst md

Study Record Dates

First Submitted

April 3, 2026

First Posted

April 9, 2026

Study Start

October 14, 2025

Primary Completion

March 20, 2026

Study Completion

March 20, 2026

Last Updated

April 9, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

De-identified individual participant data will be available upon reasonable request for academic research purposes, subject to ethics committee approval and data protection policies.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Beginning 6 months after publication and ending 5 years after publication
Access Criteria
Qualified researchers with a scientifically sound proposal may access de-identified IPD, the study protocol, SAP, and analytic code upon written request to the corresponding author, subject to ethics approval and data use agreement.
More information

Locations